Christopher Cline Sells 2,181 Shares of Travere Therapeutics (NASDAQ:TVTX) Stock

Travere Therapeutics, Inc. (NASDAQ:TVTX) CFO Christopher Cline sold 2,181 shares of Travere Therapeutics stock in a transaction dated Tuesday, May 5th. The shares were sold at an average price of $46.65, for a total value of $101,743.65. Following the completion of the transaction, the chief financial officer owned 118,968 shares in the company, valued at approximately $5,549,857.20. This represents a 1.80% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Travere Therapeutics Price Performance

Travere Therapeutics stock traded down $0.10 during midday trading on Wednesday, reaching $44.70. The company’s stock had a trading volume of 2,390,035 shares, compared to its average volume of 2,890,153. Travere Therapeutics, Inc. has a 52 week low of $13.88 and a 52 week high of $48.61. The company has a current ratio of 3.13, a quick ratio of 2.70 and a debt-to-equity ratio of 3.16. The business has a 50-day moving average price of $32.59 and a 200-day moving average price of $32.83. The stock has a market cap of $4.16 billion, a PE ratio of -194.33 and a beta of 1.13.

Travere Therapeutics (NASDAQ:TVTX) last released its earnings results on Monday, May 4th. The company reported $0.05 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.29. Travere Therapeutics had a negative return on equity of 26.16% and a negative net margin of 4.00%.The firm had revenue of $127.20 million for the quarter, compared to analysts’ expectations of $136.23 million. During the same quarter in the previous year, the business posted ($0.47) earnings per share. The business’s revenue for the quarter was up 55.6% on a year-over-year basis. On average, sell-side analysts predict that Travere Therapeutics, Inc. will post -0.16 EPS for the current year.

Key Travere Therapeutics News

Here are the key news stories impacting Travere Therapeutics this week:

• Positive Sentiment: TD Cowen raised its price target from $45 to $60 and kept a “buy” rating, implying meaningful upside vs. current levels — a bullish signal from a major sell‑side shop. TD Cowen price target raise
• Positive Sentiment: Wells Fargo upgraded its target to $50 and assigned an “overweight” rating, another near‑term positive catalyst supporting higher valuation expectations. Wells Fargo price target raise
• Neutral Sentiment: HC Wainwright reiterated a “Buy” and $57 target but trimmed FY2027–FY2030 EPS forecasts slightly (e.g., FY2027 cut from $0.71 to $0.60; FY2030 to $4.59 from $4.61). The firm still models substantial multi‑year growth, so this is more of a modest forecast tweak than a change in conviction. HC Wainwright note
• Neutral Sentiment: Earnings call transcript for Q1 2026 is available — recall Travere reported a year‑over‑year revenue gain and an EPS beat in the quarter, which helped underpin recent analyst upgrades. Review the transcript for management commentary on sparsentan commercialization and margin trajectory. Q1 2026 earnings transcript
• Negative Sentiment: Director Roy Baynes sold 9,750 shares (about $431k at the sale price) under a pre‑arranged Rule 10b5‑1 plan. Insider sales can be perceived negatively by the market despite the trading plan disclosure; monitor for any further insider activity. Insider sale filing

Hedge Funds Weigh In On Travere Therapeutics

Several institutional investors have recently added to or reduced their stakes in TVTX. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in Travere Therapeutics by 13.7% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 56,777 shares of the company’s stock valued at $1,029,000 after buying an additional 6,831 shares during the period. Norges Bank acquired a new position in shares of Travere Therapeutics during the second quarter worth approximately $1,051,000. First Trust Advisors LP acquired a new position in shares of Travere Therapeutics during the second quarter worth approximately $3,538,000. Cresset Asset Management LLC raised its position in shares of Travere Therapeutics by 26.5% during the second quarter. Cresset Asset Management LLC now owns 28,875 shares of the company’s stock worth $427,000 after purchasing an additional 6,047 shares during the period. Finally, Qube Research & Technologies Ltd raised its position in shares of Travere Therapeutics by 106.2% during the second quarter. Qube Research & Technologies Ltd now owns 604,128 shares of the company’s stock worth $8,941,000 after purchasing an additional 311,137 shares during the period.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on TVTX shares. Guggenheim boosted their price target on Travere Therapeutics from $54.00 to $56.00 and gave the stock a “buy” rating in a report on Friday, April 24th. Weiss Ratings restated a “sell (e+)” rating on shares of Travere Therapeutics in a report on Wednesday, January 21st. Citigroup boosted their price target on Travere Therapeutics from $53.00 to $59.00 and gave the stock a “buy” rating in a report on Tuesday. Piper Sandler upgraded Travere Therapeutics from a “neutral” rating to an “overweight” rating and set a $49.00 price target on the stock in a report on Tuesday, April 14th. Finally, Wall Street Zen cut Travere Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Saturday, February 21st. Ten equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $47.83.

About Travere Therapeutics

Travere Therapeutics, Inc (NASDAQ: TVTX) is a biopharmaceutical company headquartered in San Diego, California, dedicated to the development and commercialization of therapies for rare kidney and genetic disorders. The company’s mission is to address unmet needs in conditions with limited treatment options by focusing on diseases that affect small patient populations. Travere combines research, development and commercial capabilities to bring innovative medicines to market.

The company’s lead product is sparsentan, a dual endothelin angiotensin receptor antagonist that has received accelerated approval from the U.S.